Company Categories: CRO, Drug Discovery and Recombinant Proteins
Innovative Biologicals for Neuroscience Research
DetailsSeNostic provides innovative biologicals and in vitro diagnostic tools to advance neuroscience research and diagnostic tests. Specialising in high-quality recombinant proteins and state-of-the-art diagnostic platforms, SeNostic supports scientists, clinicians, and pharmaceutical companies in tackling neurodegenerative diseases like Alzheimer’s and Parkinson’s. Their products support early diagnosis, patient stratification and therapeutic screening, establishing SeNostic as a trusted partner in the pharmaceutical and life sciences sectors.
Biologicals for Neuroscience Research and Development IVD Tests
With their in-house production of recombinant proteins and the proprietary SeedCycler® technology, SeNostic offers preclinical and early diagnostic solutions, drug discovery solutions, and clinical trial resources. The company is a key partner in neurodegenerative research for leading pharmaceutical and biotech companies.
Recombinant Proteins for Neurodegenerative Biomarker Research
Recent studies have validated the superior quality of SeNostic’s recombinant proteins, with independent researchers citing that the company’s “0N3R tau was the construct that most clearly discriminated Alzheimer’s disease (AD) from control brain, and did not show any self-aggregation during a 200-hour assay runtime” (Frey et al., 2023, Acta Neuropathologica Communications). This kind of feedback underscores the reliability of SeNostic’s proteins as essential tools for developing disease models, diagnostic assays, and drug screening applications.
SeNostic’s wide range of high-quality recombinant proteins plays an essential role in neurodegenerative research. Their product portfolio includes monomeric forms of alpha-synuclein, human tau, and amyloid-beta, all designed to meet strict purity and performance standards.
Cutting-edge Technology for High-Sensitivity Biomarker Detection
SeNostic’s proprietary SeedCycler® platform is designed to detect neurodegenerative biomarkers with exceptional sensitivity and specificity, using protein “seeding” technology. In the SeedCycler® assay, misfolded proteins associated with neurodegenerative diseases serve as “seeds” that trigger aggregation in SeNostic’s recombinant proteins. This cyclic amplification, similar to PCR for proteins, enables highly accurate and early detection of small amounts of aggregated biomarkers, positioning the SeedCycler® as a groundbreaking tool for neurodegenerative diagnostics. This technology is a vital advancement for researchers aiming to diagnose and monitor diseases in preclinical stages.
SeedCycler® and AmpliStripe® for Precision Diagnostics
The SeedCycler® device, paired with SeNostic’s custom AmpliStripe® reaction vessels, optimises fluid dynamics and aggregate detection for efficient and reliable testing. The system’s rotating magnets generate shear forces, while laser detection identifies protein aggregates with high precision, making it ideal for early diagnostic applications and clinical research.
Diverse Applications in Drug Discovery, Diagnostics, and Clinical Trials
SeNostic’s products are tailored for a range of applications in neuroscience research, including:
Early Diagnostic Testing: Detecting disease-specific biomarkers in body fluids such as cerebrospinal fluid (CSF) and blood to diagnose neurodegenerative diseases in their earliest stages, supporting the development of treatment for early intervention.
Drug Discovery and Screening: The SeedCycler® assay supports pharmaceutical research by identifying compounds that may inhibit protein aggregation, aiding in the development of new therapeutics.
Clinical Trial Support: SeNostic assists in patient stratification and disease monitoring, ensuring accurate cohort selection and progression tracking in clinical trials.
Comprehensive Research Services and Trial Support
In addition to supplying high-quality recombinant proteins, SeNostic offers specialised services to accelerate drug discovery and optimise clinical trial outcomes:
Drug Research Services: Customisable protein aggregation assays to evaluate seeding activity and test the efficacy of potential therapeutic compounds.
Clinical Trial Diagnostics: Detailed analysis of CSF from clinical trial patients to refine cohort selection, track disease progression, and assess comorbidities.
Quality-Driven Production and ISO-Certified Standards
SeNostic operates with a commitment to quality and precision. Their ISO-certified facilities adhere to stringent quality standards, ensuring reliability across their product portfolio. This dedication to quality and innovation makes SeNostic a trusted provider in neuroscience research, particularly in the study of neurodegenerative diseases.
About SeNostic
Founded in 2022, after years of fundamental research, SeNostic operates from the strategic location of Hannover Medical Park, Germany. Supported by numerous research grants and industry collaborations, SeNostic’s high-quality recombinant protein offerings and cutting-edge proprietary SeedCycler® technology are revolutionising early diagnostics, clinical trial support, and drug discovery for neurodegenerative diseases. Their collaborative approach and commitment to scientific excellence and innovation make SeNostic a key player in the field of neurodegenerative disease research.
With a steadfast commitment to advancing diagnostic and therapeutic solutions, SeNostic stands at the forefront of biotech innovation, enhancing the potential for early diagnosis and effective treatments for neurodegenerative diseases worldwide.
ProductsDownloads
Innovative Drug Development Solutions for Neurodegenerative Diseases
SeNostic is Revolutionising Neurodegenerative Disease Detection and Drug Discovery with Cutting-Edge Technology A SeNostic Company Presentation SeNostic aims to enhance …
Read MoreVideosPress ReleasesContactSeNostic GmbH
Feodor-Lynen-Straße 31
30625 Hannover
GermanyPhone: +49 511 94080450
